Abstract
In this study the expression of c-erbB-3 protein was investigated in a range of human ovarian tumours using a monoclonal antibody (RTJ1) raised to a synthetic peptide from the cytoplasmic domain of the human c-erbB-3 protein. A total of 73 samples from 71 patients were graded as negative, weak, moderate or strong according to the intensity of immunohistochemical staining observed, and this was related to tumour characteristics and other clinical parameters. In terms of positivity vs negativity, of the 73 samples examined, 62 (85%) showed positive immunohistochemical staining for c-erbB-3. The majority of all ovarian tumours studied were positive for c-erbB-3 regardless of whether they were malignant (89%), borderline (100%) or benign (61%), however the incidence of positivity was significantly less in the benign group than in overtly malignant tumours (P = 0.03). c-erbB-3 positivity was not significantly associated with either age at diagnosis, tumour stage, differentiation, ploidy, percentage in S-phase or post-operative tumour bulk in malignant tumours. In terms of intensity of staining no significant difference was observed either within the common epithelial group or between this group and tumours of a benign nature. A significantly more intense pattern of c-erbB-3 staining was observed in tumours of borderline malignancy when compared with their overtly malignant counterparts (P = 0.002). Patients presenting with early-stage malignant tumours (I/II) were more likely to display intense tumour staining than those with late-stage disease (III/IV) (P = 0.04). These investigations suggest that c-erbB-3 protein is frequently expressed in both benign and malignant ovarian tumours, and that overexpression is more common in borderline and early invasive lesions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simpson, B., Weatherill, J., Miller, E. et al. c-erbB-3 protein expression in ovarian tumours. Br J Cancer 71, 758–762 (1995). https://doi.org/10.1038/bjc.1995.147
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.147
This article is cited by
-
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Cancer Cell International (2023)
-
HER3 in cancer: from the bench to the bedside
Journal of Experimental & Clinical Cancer Research (2022)
-
HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma
Virchows Archiv (2012)
-
The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
British Journal of Cancer (2011)
-
The ERBB3 receptor in cancer and cancer gene therapy
Cancer Gene Therapy (2008)